{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:33:00Z","timestamp":1761561180936},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,8,4]],"date-time":"2007-08-04T00:00:00Z","timestamp":1186185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s10620-007-9903-4","type":"journal-article","created":{"date-parts":[[2007,8,3]],"date-time":"2007-08-03T17:05:55Z","timestamp":1186160755000},"page":"647-656","source":"Crossref","is-referenced-by-count":11,"title":["Endoscopic Ulcer Rates in Healthy Subjects Associated with Use of Aspirin (81\u00a0mg\u00a0q.d.) Alone or Coadministered with Celecoxib or Naproxen: A randomized, 1-Week Trial"],"prefix":"10.1007","volume":"53","author":[{"given":"Jay L.","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Aisenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salam F.","family":"Zakko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Dodge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,8,4]]},"reference":[{"key":"9903_CR1","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","volume":"126","author":"C Patrono","year":"2004","unstructured":"Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:234S\u2013264S","journal-title":"Chest"},{"key":"9903_CR2","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373\u20132383","journal-title":"N Engl J Med"},{"key":"9903_CR3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71\u201386","journal-title":"BMJ"},{"key":"9903_CR4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/hc3801.097475","volume":"104","author":"SC Smith Jr","year":"2001","unstructured":"Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA (2001) AHA\/ACC Scientific Statement: AHA\/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 104:1577\u20131579","journal-title":"Circulation"},{"key":"9903_CR5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","volume":"310","author":"J Weil","year":"1995","unstructured":"Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P (1995) Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310:827\u2013830","journal-title":"BMJ"},{"key":"9903_CR6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","volume":"55","author":"A Lanas","year":"2006","unstructured":"Lanas A, Garcia-Rodriguez LA, Arroyo MT, Gomollon F, Feu F, Gonzalez-Perez A, Zapata E, Bastida G, Rodrigo L, Santolaria S, Guell M, de Argila CM, Quintero E, Borda F, Pique JM, Asociacion Espanola de Gastroenterologia (2006) Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 55:1731\u20131738","journal-title":"Gut"},{"key":"9903_CR7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archinte.164.11.1243","volume":"164","author":"ER Cox","year":"2004","unstructured":"Cox ER, Frisse M, Behm A, Fairman KA (2004) Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med 164:1243\u20131246","journal-title":"Arch Intern Med"},{"key":"9903_CR8","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1111\/j.1572-0241.2005.50565.x","volume":"100","author":"B Cryer","year":"2005","unstructured":"Cryer B, Goldstein J, Amer F, Hunt B (2005) In low-dose aspirin users: endoscopic gastroduodenal ulcer rates comparing the combination of lansoprazole 30\u00a0mg QD and naproxen 500\u00a0mg BID vs celecoxib 200\u00a0mg QD [abstract]. Am J Gastroenterol 100:S59","journal-title":"Am J Gastroenterol"},{"key":"9903_CR9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1365-2036.2006.02912.x","volume":"23","author":"JL Goldstein","year":"2006","unstructured":"Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE (2006) The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a nonselective nonsteroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 23:1489\u20131498","journal-title":"Aliment Pharmacol Ther"},{"key":"9903_CR10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","volume":"127","author":"L Laine","year":"2004","unstructured":"Laine L, Maller ES, Yu C, Quan H, Simon T (2004) Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127:395\u2013402","journal-title":"Gastroenterology"},{"key":"9903_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/J354v20n03_03","volume":"20","author":"JE Biskupiak","year":"2006","unstructured":"Biskupiak JE, Brixner DI, Howard KB, Oderda GM (2006) Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother 20:7\u201314","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"9903_CR12","doi-asserted-by":"crossref","first-page":"A-469","DOI":"10.1053\/gast.2002.31102","volume":"122","author":"JL Goldstein","year":"2002","unstructured":"Goldstein JL, on behalf of the CLASS investigators (2002) Gastrointestinal (GI) event rates in the CLASS study: 6-month vs longer-term follow-up analyses [abstract]. Gastroenterology 122:A-469","journal-title":"Gastroenterology"},{"key":"9903_CR13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(04)16893-1","volume":"364","author":"TJ Schnitzer","year":"2004","unstructured":"Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364:665\u2013674","journal-title":"Lancet"},{"key":"9903_CR14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1572-0241.2001.03740.x","volume":"96","author":"JL Goldstein","year":"2001","unstructured":"Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS (2001) Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 96:1019\u20131027","journal-title":"Am J Gastroenterol"},{"key":"9903_CR15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0016-5085(99)70545-7","volume":"117","author":"B Cryer","year":"1999","unstructured":"Cryer B, Feldman M (1999) Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117:17\u201325","journal-title":"Gastroenterology"},{"key":"9903_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","volume":"119","author":"G Singh","year":"2006","unstructured":"Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators (2006) Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 119:255\u2013266","journal-title":"Am J Med"},{"key":"9903_CR17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520\u20131528","journal-title":"N Engl J Med"},{"key":"9903_CR18","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, Derry S, Makinson GT, McQuay HJ (2005) Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 7:R644\u2013R665","journal-title":"Arthritis Res Ther"},{"key":"9903_CR19","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247\u20131255","journal-title":"JAMA"},{"key":"9903_CR20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092\u20131102","journal-title":"N Engl J Med"},{"key":"9903_CR21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071\u20131080","journal-title":"N Engl J Med"},{"key":"9903_CR22","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.106.636746","volume":"114","author":"SD Solomon","year":"2006","unstructured":"Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J, APC, PreSAP Trial Investigators (2006) Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114:1028\u20131035","journal-title":"Circulation"},{"key":"9903_CR23","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330:1366","journal-title":"BMJ"},{"key":"9903_CR24","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","volume":"332","author":"PM Kearney","year":"2006","unstructured":"Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 332:1302\u20131308","journal-title":"BMJ"},{"key":"9903_CR25","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.296.13.jrv60015","volume":"296","author":"J Zhang","year":"2006","unstructured":"Zhang J, Ding EL, Song Y (2006) Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 296:1619\u20131632","journal-title":"JAMA"},{"key":"9903_CR26","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1633\u20131644","journal-title":"JAMA"},{"key":"9903_CR27","first-page":"740","volume":"10","author":"AM Fendrick","year":"2004","unstructured":"Fendrick AM (2004) COX-2 inhibitor use after Vioxx: careful balance or end of the rope? Am J Manag Care 10:740\u2013741","journal-title":"Am J Manag Care"},{"key":"9903_CR28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ncpgasthep0610","volume":"3","author":"FK Chan","year":"2006","unstructured":"Chan FK (2006) Primer: managing NSAID-induced ulcer complications\u2013balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 3:563\u2013573","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"9903_CR29","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1161\/CIRCULATIONAHA.105.602425","volume":"113","author":"F Andersohn","year":"2006","unstructured":"Andersohn F, Suissa S, Garbe E (2006) Use of first- and second-generation cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 113:1950\u20131957","journal-title":"Circulation"},{"key":"9903_CR30","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(06)69666-9","volume":"368","author":"CP Cannon","year":"2006","unstructured":"Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368:1771\u20131781","journal-title":"Lancet"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-9903-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-007-9903-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-9903-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:43:45Z","timestamp":1559245425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-007-9903-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["9903"],"URL":"https:\/\/doi.org\/10.1007\/s10620-007-9903-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,4]]}}}